IBOK
BCRX icon

Independence Bank of Kentucky’s BioCryst Pharmaceuticals BCRX Stock Holding History

Independence Bank of Kentucky’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.25K Sell
225
-100
-31% -$904 ﹤0.01% 565
2026
Q1 		$3.09K Sell
325
-75
-19% -$582 ﹤0.01% 583
2025
Q4 		$3.12K Buy
+400
New +$2.89K ﹤0.01% 614

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
IMC Chicago
IMC Chicago Chicago, Illinois $419B AUM 72.04% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Independence Bank of Kentucky's BCRX Position: Q2 2026 in Review

Independence Bank of Kentucky reduced its BioCryst Pharmaceuticals (BCRX) stake by 31% in Q2 2026, selling an estimated $904 and leaving 225 shares worth $2.25K. The position accounts for ﹤0.01% of the portfolio, ranked #565.

Independence Bank of Kentucky first reported a position in BCRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.12K in Q4 2025. 115 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Independence Bank of Kentucky held 225 shares of BioCryst Pharmaceuticals worth $2.25K as of Q2 2026.
  • Independence Bank of Kentucky sold 100 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $904.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Independence Bank of Kentucky's portfolio in Q2 2026, its #565 holding.
  • Independence Bank of Kentucky first reported a position in BioCryst Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Independence Bank of Kentucky's BioCryst Pharmaceuticals position peaked at $3.12K in Q4 2025.
  • 115 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Independence Bank of Kentucky's 13F filing for Q2 2026, filed 13 Jul 2026.